Comparative pharmacoepidemiological assessment of antianginal, antiplatelet and lipid-lowering drugs in patients with stable angina in outpatient practice in Kursk and Chisinau


Cite item

Full Text

Abstract

Aim. To study structure of medical purposes of anti-anginal, antiplatelet and hypolipidemic means at coronary heart disease patients in ambulatory practice of Kursk (Russian Federation) and Chisinau (Republic of Moldova). Materials and methods. During the period from October, 2017 to January, 2018 as a one-stage descriptive research, questioning of doctors of the medical organizations of Kursk and Chisinau was carried out. Questionnaires included questions on pharmacoepidemiological aspects of purpose of antianginal, antiplatelet and hypolipidemic means. Total number of respondents was 132, of them 66 (2 cardiologists and 64 therapists) - in Kursk and 66 (10 cardiologists and 56 therapists) - in Chisinau. Results. Doctors of Kursk and Chisinau have no statistically significant differences in structure of appointments of the main groups of anti-anginal means, antiplatelet and hypolipidemic drugs. The tendency to more frequent use of blockers of calcium channels and nitrovazodilatator among doctors of Chisinau while in structure of appointments of doctors of Kursk some prevalence of a trimetazidin, antiagregants and statines was noted was noted (p>0.05). Leaders in group of beta blockers were bisoprolol and metoprolol in the conditions of the pharmaceutical market of Kursk and Chisinau. Priority of the choice of blockers of calcium channels authentically differed in the considered regions only on a felodipin - in Kursk appointed it to a thicket (p<0.01). The structure of the choice of various representatives of nitrovazodilatator practically was parity in the explored regions. The leading drug from group of antiagregant the Kursk and Chisinau doctors had acetylsalicylic acid (58.1 and 76.3% respectively) while differences in use of a klopidogrel were more essential (41.9 and 23.7% respectively, p<0.05). Hypolipidemic means were provided by statines. The leading drugs from this group were rosuvastatin, atorvastatin and simvastatin. The share of purposes of two last medicines authentically differed. So in Kursk was more demanded (p<0.05), and in Chisinau - simvastatin (p<0.01). Conclusion. Priority classes in structure of assignment anti-anginal agents according to questioning of doctors of Kursk and Chisinau were b-blockers, blockers of calcic channels. Frequency of use of antiagregants and statins was comparable in the compared regions. The main share of medical assignments in the conditions of Kursk and Chisinau considered as in the relation the anti-anginal agents, and antiagregants, statins corresponds to the existing recommendations about pharmacotherapy of patients with stable angina pectoris.

About the authors

Sergey V. Povetkin

State Medical University

Email: clinfarm@kursknet
D. Sci. (Med.), Prof. Kursk, Russia

Oxana V. Levashova

State Medical University

Cand. Sci. (Med.) Kursk, Russia

Elena G. Klyueva

State Medical University

Cand. Sci. (Med.) Kursk, Russia

Victor I. Ghicavii

Nicolae Testemitanu State University of Medicine and Pharmacy

D. Sci. (Med.), Prof. Chisinau, Republic of Moldova

Nicolae G. Batchinschi

Nicolae Testemitanu State University of Medicine and Pharmacy

D. Sci. (Med.), Prof. Chisinau, Republic of Moldova

Lilia A. Pjdgurschi

Nicolae Testemitanu State University of Medicine and Pharmacy

Cand. Sci. (Med.) Chisinau, Republic of Moldova

Lucia M. Turcan

Nicolae Testemitanu State University of Medicine and Pharmacy

Cand. Sci. (Med.) Chisinau, Republic of Moldova

References

  1. Основные причины смертности в Молдове - болезни сердца и онкология. https://omg.md/index.php?newsid=9974 @@Osnovnye prichiny smertnosti v Moldove - bolezni serdtsa i onkologiia. https://omg.md/index.php?newsid=9974 (in Russian)
  2. Щербакова Е.М. Демографические итоги I полугодия 2018 года в России. Часть II. Демоскоп Weekly. 2018: 781-2. http://demoscope.ru/weekly/2018/0781/barom01.php @@Shcherbakova E.M. Demograficheskie itogi I polugodiia 2018 goda v Rossii. Chast' II. Demoskop Weekly. 2018: 781-2. http://demoscope.ru/weekly/2018/0781/barom01.php (in Russian)
  3. Angina pectorală stabilă. Protocolului clinic naţional. Republica Moldova, 2017.
  4. Dislipidemiile. Protocolului clinic naţional. Republica Moldova, 2017.
  5. Tromboembolismul pulmonar. Protocolului clinic naţional. Republica Moldova, 2017.
  6. Лупанов В.П. Вторичная медикаментозная профилактика ишемической болезни сердца и инфаркта миокарда. Мед. совет. 2013; 3: 86-91. doi: 10.21518/2079-701X-2013-3-86-91 @@Lupanov V.P. Vtorichnaia medikamentoznaia profilaktika ishemicheskoi bolezni serdtsa i infarkta miokarda. Med. sovet. 2013; 3: 86-91. doi: 10.21518/2079-701X-2013-3-86-91 (in Russian)
  7. Оганов Р.Г., Лепахин В.К., Фитилев С.Б. и др. Особенности диагностики и терапии стабильной стенокардии в Российской Федерации (международное исследование ATP-Angina Treatment Pattern). Кардиология. 2003; 5: 9-15.@@Oganov R.G., Lepakhin V.K., Fitilev S.B. et al. Osobennosti diagnostiki i terapii stabil'noi stenokardii v Rossiiskoi Federatsii (mezhdunarodnoe issledovanie ATP-Angina Treatment Pattern). Kardiologiia. 2003; 5: 9-15 (in Russian)
  8. Шальнова С.А., Оганов Р.Г., Стег Ф.Г., Форд Й. Ишемическая болезнь сердца. Современная реальность по данным всемирного регистра CLARIFY. Кардиология. 2013; 53 (8): 28-33. @@Shal'nova S.A., Oganov R.G., Steg F.G., Ford I. Ishemicheskaia bolezn' serdtsa. Sovremennaia real'nost' po dannym vsemirnogo registra CLARIFY. Kardiologiia. 2013; 53 (8): 28-33. (in Russian)
  9. Insuficienţa cardiacă acută şi cronică la adult. Protocolului clinic naţional. Republica Moldova, 2017.
  10. Kloner R.A, Chaitman B. Angina and Its Management. J Cardiovasc Pharmacol Ther 2017; 22 (3). https://doi.org/ 10.1177/ 1074248416679733
  11. Samohvalov E, Grejdieru A, Grib L et al. Management of stable angina in men (Literature review). Jurnalul Sănătate Publică, Economie şi Management în Medicină 2017; 3 (73): 170-2.
  12. Боровиков В.П., Боровиков И.П. STATISTICA. Статистический анализ и обработка данных в среде Windows. М.: Филинъ, 1998. @@Borovikov V.P., Borovikov I.P. STATISTICA. Statistical analysis and data processing in a Windows. Moscow: Filin, 1998 (in Russian)
  13. Гланц С. Медико-биологическая статистика. М.: Практика, 1999. [Glantz S. Medico-biological statistics. Moscow: Praktika, 1999 (in Russian)
  14. Бубнова М.Г., Аронов Д.М., Оганов Р.Г. и др. Клиническая характеристика и общие подходы к лечению пациентов со стабильной стенокардией в реальной практике. Российское исследование ПЕРСПЕКТИВА (часть I). Кардиоваскулярная терапия и профилактика. 2010; 9 (6): 47-55. @@Bubnova M.G., Aronov D.M., Oganov R.G. et al. Clinical characteristic and the general approaches to treatment of patients with stable stenocardia in real practice. Kardiovaskuliarnaia terapiia i profilaktika. 2010; 9 (6): 47-55 (in Russian)
  15. Погосова Г.В., Оганов Р.Г., Колтунов И.Е. и др. Мониторинг вторичной профилактики ишемической болезни сердца в России и странах Европы: результаты международного многоцентрового исследования EUROASPIRE III. Кардиология. 2011; 1: 34-40. @@Pogosova G.V., Oganov R.G., Koltunov I.E. et al. Monitoring vtorichnoi profilaktiki ishemicheskoi bolezni serdtsa v Rossii i stranakh Evropy: rezul'taty mezhdunarodnogo mnogotsentrovogo issledovaniia EUROASPIRE III. Kardiologiia. 2011; 1: 34-40 (in Russian)
  16. Погосова Н.В., Оганов Р.Г., Бойцов С.А. и др. Медикаментозная терапия у пациентов с ишемической болезнью сердца в России и Европе: результаты российской части международного многоцентрового исследования EUROASPIRE IV. Кардиология. 2016; 12: 11-19. @@Pogosova N.V., Oganov R.G., Boitsov S.A. et al. Medikamentoznaia terapiia u patsientov s ishemicheskoi bolezn'iu serdtsa v Rossii i Evrope: rezul'taty rossiiskoi chasti mezhdunarodnogo mnogotsentrovogo issledovaniia EUROASPIRE IV. Kardiologiia. 2016; 12: 11-19 (in Russian)
  17. Степина Е.В., Лукьянов М.М., Бичурина М.А. и др. Назначение медикаментозной терапии, влияющей на прогноз у больных с фибрилляцией предсердий в сочетании с артериальной гипертонией, ишемической болезнью сердца, хронической сердечной недостаточностью по данным регистра РЕКВАЗА-КЛИНИКА. Кардиоваскулярная терапия и профилактика. 2017; 16 (2): 33-8. doi: 10.15829/1728-8800-2017-2-33-38 @@Stepina E.V., Luk'ianov M.M., Bichurina M.A. et al. Naznachenie medikamentoznoi terapii, vliiaiushchei na prognoz u bol'nykh s fibrilliatsiei predserdii v sochetanii s arterial'noi gipertoniei, ishemicheskoi bolezn'iu serdtsa, khronicheskoi serdechnoi nedostatochnost'iu po dannym registra REKVAZA-KLINIKA. Kardiovaskuliarnaia terapiia i profilaktika. 2017; 16 (2): 33-8. doi: 10.15829/1728-8800-2017-2-33-38 (in Russian)
  18. Фитилев С.Б., Шкребнева И.И., Возжаев А.В. и др. Тенденции применения антиангинальных препаратов в специализированном амбулаторном учреждении за пятилетний период. Фарматека. 2017; 15: 49-54. @@Fitilev S.B., Shkrebneva I.I., Vozzhaev A.V. et al. Tendentsii primeneniia antianginal'nykh preparatov v spetsializirovannom ambulatornom uchrezhdenii za piatiletnii period. Farmateka. 2017; 15: 49-54 (in Russian)
  19. Ghicavîi V, Bacinschi N, Guşuilă Gh. Farmacologie (ed. a 3-a (rev. si compl.). Ch: F.E.-P. "Tipogr. Centrală", 2012.
  20. Фитилев С.Б., Шкребнева И.И., Возжаев А.В., Цуканова К.О. Пятилетняя динамика вторичной медикаментозной профилактики у пациентов со стабильной стенокардией на уровне специализированного амбулаторного звена г. Москвы (фармакоэпидемиологическое исследование). Рациональная фармакотерапия в кардиологии. 2018; 14 (2): 244-51. doi: 10.20996/1819-6446-2018-14-2-244-251 @@Fitilev S.B., Shkrebneva I.I., Vozzhaev A.V., Tsukanova K.O. Piatiletniaia dinamika vtorichnoi medikamentoznoi profilaktiki u patsientov so stabil'noi stenokardiei na urovne spetsializirovannogo ambulatornogo zvena g. Moskvy (farmakoepidemiologicheskoe issledovanie). Ratsional'naia farmakoterapiia v kardiologii. 2018; 14 (2): 244-51. doi: 10.20996/1819-6446-2018-14-2-244-251 (in Russian)
  21. Польшакова И.Л., Поветкин С.В. Структура лекарственной терапии и клиническая характеристика больных с фибрилляцией предсердий по данным исследования РЕКУР-ФП. Рациональная фармакотерапия в кардиологии. 2018; 14 (5): 733-40. doi: 10.20996/1819- 6446-2018-14-5-733-740 @@Pol'shakova I.L., Povetkin S.V. Struktura lekarstvennoi terapii i klinicheskaia kharakteristika bol'nykh s fibrilliatsiei predserdii po dannym issledovaniia REKUR-FP. Ratsional'naia farmakoterapiia v kardiologii. 2018; 14 (5): 733-40. DOI: 10.20996/ 1819- 6446-2018-14-5-733-740 (in Russian).]
  22. Толпыгина С.Н., Марцевич С.Ю. Изучение динамики частоты приема основных классов лекарственных препаратов, показанных при лечении пациентов с хронической ишемической болезнью сердца, с 2004 по 2014 г. Данные регистра прогноз ИБС. Клиницист. 2016; 1: 29-35. DOI: 35. doi: 10.17650/1818-8338-2016-10-1-29-35 @@Tolpygina S.N., Martsevich S.Iu. Izuchenie dinamiki chastoty priema osnovnykh klassov lekarstvennykh preparatov, pokazannykh pri lechenii patsientov s khronicheskoi ishemicheskoi bolezn'iu serdtsa, s 2004 po 2014 g. Dannye registra prognoz IBS. Klinitsist. 2016; 1: 29-35. doi: 10.17650/1818-8338-2016-10-1-29-35 (in Russian)
  23. Стабильная ишемическая болезнь сердца. Клинические рекомендации, 2016. http://cr.rosminzdrav.ru/#!/recomend/133/

Copyright (c) 2019 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies